<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00298870</url>
  </required_header>
  <id_info>
    <org_study_id>PG-MRT-TB-01</org_study_id>
    <nct_id>NCT00298870</nct_id>
  </id_info>
  <brief_title>Randomized Trial for Pharmacogenomics-based Tuberculosis Therapy (RT-PGTT)</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Osaka University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Osaka University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to elucidate whether the individualized medicine based on NAT2
      gene polymorphism could improve the safety, efficacy and economical benefits of multi-drug
      therapy for the pulmonary tuberculosis with isoniazid.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2005</start_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidences of unfavorable events in two different treatment regimens based on the NAT2 gene polymorphism</measure>
    <description>1) the incidences of drug-induced liver injury associated with INH that occurred within 8 weeks of the treatments, and 2) the incidence of early treatment failure as indicated by a persistent positive culture or no improvement in chest radiographs at the 8th week</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Other adversed events during the 8 weeks of the intensive phase of the anti-tuberculosis therapy</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">172</enrollment>
  <condition>Pulmonary Tuberculosis</condition>
  <arm_group>
    <arm_group_label>PGx-treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>NAT2 genotype-guided treatment with stratified isoniazid dose (approx. 7.5 mg/kg b.w., patients homozygous for NAT2*4: rapid acetylators; 5 mg/kg, patients heterozygous for NAT2*4: intermediate acetylators; 2.5 mg/kg, patientes without NAT2*4: slow acetylators)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>STD-treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with conventional standard isoniazid dose (approx. 5 mg/kg b.w.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isoniazid</intervention_name>
    <description>Modified daily isoniazid dose : approx. 7.5 mg/kg, 5 mg/kg and 2.5 mg/kg for rapid, intermediate and slow acetylators, respectively</description>
    <arm_group_label>PGx-treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>isoniazed</intervention_name>
    <description>Conventional standard daily isoniazid dose : approx. 5 mg/kg b.w. for all</description>
    <arm_group_label>STD-treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Newly diagnosed pulmonary tuberculosis patients

          -  Informed consent including pharmacogenomic analysis

        Exclusion Criteria:

          -  Abnormal liver and kidney function test before treatment

          -  Long-term use of steroids and/or immunodepressants

          -  Inadequate clinical conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junichi Azuma, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Graduate School of Pharmaceutical Sciences, Osaka University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Osaka Prefectural Medical Center for Respiratory and Allergic Diseases</name>
      <address>
        <city>Habikino</city>
        <state>Osaka</state>
        <zip>583-8588</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Osaka Hospital, Anti-Tuberculosis Association, Osaka Branch</name>
      <address>
        <city>Neyagawa</city>
        <state>Osaka</state>
        <zip>572-0801</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Kinki-chuo Chest Medical Center</name>
      <address>
        <city>Sakai</city>
        <state>Osaka</state>
        <zip>591-8555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Toneyama</name>
      <address>
        <city>Toyonaka</city>
        <state>Osaka</state>
        <zip>560-8552</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2006</study_first_submitted>
  <study_first_submitted_qc>March 2, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2006</study_first_posted>
  <last_update_submitted>October 17, 2012</last_update_submitted>
  <last_update_submitted_qc>October 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 18, 2012</last_update_posted>
  <keyword>pulmonary tuberculosis</keyword>
  <keyword>isoniazid</keyword>
  <keyword>arylamine N-acetyltransferase 2</keyword>
  <keyword>pharmacogenomics</keyword>
  <keyword>genetic polymorphisms</keyword>
  <keyword>individualized medicine</keyword>
  <keyword>drug-induced hepatotoxity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
    <mesh_term>Tuberculosis, Pulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isoniazid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

